Imagine you have a severe urinary tract infection. Your doctor prescribes a standard antibiotic, one that has worked for years. But this time, the medication fails. The infection worsens. This scenario is becoming more common in Pakistan.
A new review of recent studies shows a troubling trend. The antibiotics doctors rely on most are losing their power. This is not a distant problem. It affects families, communities, and the country's ability to fight disease.
The World Health Organization has a goal. It wants 70% of all antibiotic use worldwide to be from its "Access" list. These are the safest, most effective drugs for common infections. Pakistan's current data suggests this target is out of reach.
This is a public health emergency in slow motion.
For years, the medical community has warned about antibiotic overuse. In Pakistan, weak surveillance and irrational prescribing have made the problem worse. When antibiotics are used too often or for the wrong reasons, bacteria learn to resist them. This is how resistance spreads.
The United Nations General Assembly has declared this a global crisis. Every country is supposed to track its antibiotic use and push for safer choices. But without good data, it is hard to know if efforts are working. This review fills a critical gap by looking at the most recent data from Pakistan.
The old way of thinking assumed that standard antibiotics would always be there as a backup. But here is the twist. The backup is failing. The review shows that for many common bacteria, the first-line drugs are no longer reliable.
Think of bacteria as a lock and antibiotics as the key. Resistance is like the lock changing its shape. The old key no longer fits. Doctors need new keys, but developing them takes years. In the meantime, patients are at risk.
This review did not run a new experiment. Instead, researchers gathered and analyzed 74 studies from 2020 to 2024. They looked at how well WHO Access antibiotics worked against bacteria taken from human patients. The studies came from across Pakistan, with most from the Punjab region.
The findings are clear and concerning. Overall, the susceptibility of WHO Access antibiotics remains low across major pathogens. This means the drugs are not working as they should.
For example, susceptibility for Staphylococcus aureus and Pseudomonas species showed notable declines. These bacteria can cause skin infections, pneumonia, and blood infections. E. coli, a common cause of urinary tract infections, showed variable susceptibility. This means the drug works sometimes but fails unpredictably.
When researchers looked at antibiotic classes, the picture was similar. Aminoglycosides, beta-lactams, and cephalosporins all showed low susceptibility. These are not obscure drugs. They are the backbone of treatment for many infections.
But there is a catch. This review looks at susceptibility, not actual prescribing patterns. It shows the drugs are not working well, but it does not show how often doctors are still using them. That is a separate but related problem.
The data points to a difficult reality. If the most common antibiotics are failing, achieving the 70% Access target becomes a huge challenge. The goal is not just about using more of these drugs. It is about using them when they will actually work.
Experts in the field emphasize that surveillance is the first step. You cannot fix a problem you cannot measure. Pakistan needs stronger systems to track resistance and prescribing in real time. This review is a start, but it is not enough.
For patients and caregivers, this means being vigilant. If a doctor prescribes an antibiotic, it is okay to ask questions. Why this drug? Is it on the Access list? Are there alternatives if this one fails? Open communication can help.
This does not mean all antibiotics are useless. Some still work, and new ones are in development. But the options are shrinking, and the clock is ticking.
The review has limitations. It is a scoping review, not a full clinical trial. It summarizes existing studies, which may vary in quality. It also focuses on susceptibility, not on patient outcomes like survival or hospital stay.
What happens next? Pakistan must strengthen its surveillance programs. This means more hospitals testing bacteria and reporting results. It also means educating doctors and patients about antibiotic use. The goal is to preserve the drugs we have left while we search for new ones.
Global efforts will take time. Research is slow, and new antibiotics are expensive. But the path is clear. Without action, common infections could become deadly again. The 70% target is a guide, not a guarantee. It will take hard work to get there.
